Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer

NCT03367702 is registered in ClinicalTrials.gov with NRG Oncology as lead sponsor.

NCT NCT03367702
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03367702 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
Lead sponsor
NRG Oncology
Phase
Phase 3
Overall status
Active, not recruiting
Start date
February 1, 2018
Completion date
December 1, 2027
Enrollment
692 (estimated)
Sites
293

Conditions

As the registry lists them; a condition with its own page is linked.

stage ii prostate adenocarcinoma ajcc v7